Lyra Therapeutics, Inc. (Nasdaq: LYRA), a US-based clinical-stage therapeutics company, announced on Tuesday that it has named Richard Nieman, MD as its new chief medical officer, effective 11 July 2022.
Dr Nieman has over 25 years of experience in drug development and medical affairs. He is a respiratory physician (pulmonologist) with deep pharmaceutical medicine experience. He has served as SVP & worldwide medical head of Immunology at Bristol Myers Squibb (BMS), head of R&D China at BMS, global medical officer & head of Medical at Teva, and head of Asia Pacific Medical at Bayer. He has headed the company's medical and health economic and outcome research (HEOR) function of 550 professionals and was a member of the Specialty Executive Team. He is a Fellow of the UK Royal College of Physicians, a visiting senior lecturer at the School of Cancer and Pharmaceutical Sciences, Kings College, London, and was a visiting professor at Fudan University School of Public Health in Shanghai, China.
Maria Palasis, PhD, Lyra Therapeutics CEO, said, 'We're pleased to welcome Dr Nieman as our chief medical officer. Dr Nieman joins the Lyra team at a critical time with our lead candidate LYR-210 in pivotal Phase 3 trials. Having successfully developed and launched numerous innovative medicines for patients and their families during the course of his career, his experience building and leading medical organisations will be invaluable as we work to bring new treatments to patients with chronic rhinosinusitis (CRS).'
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib